BioCentury
ARTICLE | Distillery Therapeutics

Dental

April 25, 2017 3:59 PM UTC

Studies in mice suggest inhibiting epoxide hydrolase could help treat periodontal bone loss. In a mouse model of bacterial infection-induced periodontitis, a previously reported epoxide hydrolase inhibitor decreased alveolar bone loss compared with vehicle. Also in the model, systemic knockout of epoxide hydrolase decreased alveolar bone loss compared with normal expression. Next steps by EicOsis LLC could include testing epoxide hydrolase inhibitors in additional models of periodontitis.

GlaxoSmithKline plc has 2256294, an epoxide hydrolase inhibitor, in Phase I testing for chronic obstructive pulmonary disease (COPD)...

BCIQ Company Profiles

University of California Davis

BCIQ Target Profiles

Epoxide hydrolase